Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX(R) AR-V7 Nucleus Detect(TM) Test to Predict Treatment Response in Metastatic Disease

New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer REDWOOD CITY, Calif., Feb. 26, 2018 -- (Healthcare Sales & Marketing Network) -- Genomic Health, Inc. ... Diagnostics, Oncology, Product Launch Genomic Health, Oncotype DX, AR-V7 Nucleus Detect, liquid biopsy, mCRPC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news